A detailed history of Ubs Group Ag transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 45,775 shares of URGN stock, worth $505,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,775
Previous 11,887 285.08%
Holding current value
$505,355
Previous $199,000 191.96%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.7 - $17.92 $430,377 - $607,272
33,888 Added 285.08%
45,775 $581,000
Q2 2024

Aug 13, 2024

SELL
$12.72 - $19.2 $394,065 - $594,816
-30,980 Reduced 72.27%
11,887 $199,000
Q1 2024

May 13, 2024

BUY
$13.81 - $19.33 $245,790 - $344,035
17,798 Added 71.0%
42,867 $643,000
Q4 2023

Feb 09, 2024

BUY
$10.87 - $15.93 $63,589 - $93,190
5,850 Added 30.44%
25,069 $376,000
Q3 2023

Nov 09, 2023

BUY
$8.84 - $22.64 $45,181 - $115,713
5,111 Added 36.23%
19,219 $269,000
Q2 2023

Aug 11, 2023

BUY
$8.75 - $14.29 $123,445 - $201,603
14,108 New
14,108 $146,000
Q4 2022

Feb 08, 2023

SELL
$7.55 - $11.96 $157,900 - $250,131
-20,914 Reduced 47.98%
22,675 $201,000
Q3 2022

Nov 10, 2022

BUY
$7.21 - $9.41 $127,753 - $166,735
17,719 Added 68.49%
43,589 $363,000
Q2 2022

Aug 10, 2022

SELL
$5.12 - $8.74 $145,720 - $248,749
-28,461 Reduced 52.38%
25,870 $212,000
Q1 2022

May 16, 2022

BUY
$5.92 - $9.73 $39,516 - $64,947
6,675 Added 14.01%
54,331 $473,000
Q4 2021

Feb 14, 2022

BUY
$9.03 - $19.13 $418,495 - $886,579
46,345 Added 3535.09%
47,656 $453,000
Q3 2021

Nov 15, 2021

BUY
$14.31 - $18.39 $5,881 - $7,558
411 Added 45.67%
1,311 $22,000
Q2 2021

Aug 13, 2021

SELL
$15.2 - $20.94 $100,654 - $138,664
-6,622 Reduced 88.04%
900 $14,000
Q1 2021

May 12, 2021

SELL
$17.99 - $26.96 $79,227 - $118,731
-4,404 Reduced 36.93%
7,522 $147,000
Q4 2020

Feb 11, 2021

BUY
$17.54 - $25.43 $164,612 - $238,660
9,385 Added 369.34%
11,926 $215,000
Q3 2020

Nov 12, 2020

SELL
$18.81 - $26.42 $123,393 - $173,315
-6,560 Reduced 72.08%
2,541 $49,000
Q2 2020

Jul 31, 2020

SELL
$16.5 - $29.7 $38,923 - $70,062
-2,359 Reduced 20.58%
9,101 $237,000
Q1 2020

May 01, 2020

SELL
$13.68 - $34.6 $142,272 - $359,840
-10,400 Reduced 47.58%
11,460 $204,000
Q4 2019

Feb 14, 2020

BUY
$21.11 - $34.86 $166,051 - $274,208
7,866 Added 56.21%
21,860 $730,000
Q3 2019

Nov 14, 2019

BUY
$23.83 - $36.44 $251,049 - $383,895
10,535 Added 304.57%
13,994 $334,000
Q2 2019

Aug 14, 2019

BUY
$32.75 - $40.35 $23,219 - $28,608
709 Added 25.78%
3,459 $124,000
Q1 2019

May 14, 2019

SELL
$35.47 - $54.55 $55,794 - $85,807
-1,573 Reduced 36.39%
2,750 $102,000
Q4 2018

Feb 14, 2019

BUY
$38.35 - $50.39 $41,149 - $54,068
1,073 Added 33.02%
4,323 $186,000
Q3 2018

Nov 14, 2018

SELL
$41.65 - $51.7 $91,963 - $114,153
-2,208 Reduced 40.45%
3,250 $154,000
Q2 2018

Aug 14, 2018

BUY
$48.35 - $65.33 $89,302 - $120,664
1,847 Added 51.15%
5,458 $272,000
Q1 2018

May 15, 2018

BUY
$38.64 - $57.54 $33,423 - $49,772
865 Added 31.5%
3,611 $180,000
Q4 2017

Feb 14, 2018

BUY
$27.28 - $43.26 $47,630 - $75,531
1,746 Added 174.6%
2,746 $102,000
Q3 2017

Nov 14, 2017

BUY
$17.15 - $32.72 $10,753 - $20,515
627 Added 168.1%
1,000 $32,000
Q2 2017

Aug 14, 2017

BUY
N/A
373
373 $7,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $251M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.